ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung.
Saved in:
| Title: | ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung. |
|---|---|
| Authors: | Schuijs MJ; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Png S; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Richard AC; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK., Tsyben A; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Hamm G; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Stockis J; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Garcia C; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Pinaud S; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Nicholls A; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Ros XR; Bioscience Asthma, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Su J; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Eldridge MD; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Riedel A; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Serrao EM; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Rodewald HR; Division of Cellular Immunology, German Cancer Research Center, Heidelberg, Germany., Mack M; Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany., Shields JD; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Cohen ES; Bioscience Asthma, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., McKenzie ANJ; MRC Laboratory of Molecular Biology, Cambridge, UK., Goodwin RJA; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK., Brindle KM; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.; Department of Biochemistry, University of Cambridge, Cambridge, UK., Marioni JC; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.; EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK., Halim TYF; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK. Tim.Halim@cruk.cam.ac.uk. |
| Source: | Nature immunology [Nat Immunol] 2020 Sep; Vol. 21 (9), pp. 998-1009. Date of Electronic Publication: 2020 Aug 03. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
